Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacteremia Due to Staphylococcus Aureus Clear all
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Recruiting Phase 4 Interventional

Combination Antibiotic Therapy for Staphylococcus Aureus Bacteremia

NCT07376889
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Antibiotic Monotherapy (AM) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Antibiotic Monotherapy (AM) for patients with methicillin-resistant S. aureus bacteremia (MRSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-sensitive S. aureus bacteremia (MSSAB), Combination Antibiotic Therapy (CAT) for patients with methicillin-resistant S. aureus bacteremia (MRSAB)
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
2,096 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Brighton, Colorado • Denver, Colorado • Grand Junction, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Withdrawn Phase 2 Interventional

ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis

NCT05329168
View directory record Official record
Conditions
Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
Interventions
Tonabacase (LSVT-1701)
Drug
Lead sponsor
Lysovant
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 20, 2026, 7:45 PM EDT
Withdrawn Phase 4 Interventional

Oritavancin for Staphylococcus Aureus Infections in Opioid Users

NCT03761953
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Oritavancin Injection
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 20, 2026, 7:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Virulence Determinants in S Aureus Bacteremia

NCT00319826
View directory record Official record
Conditions
Bacteremia
Interventions
No intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

NCT00062647
View directory record Official record
Conditions
Gram-Positive Bacterial Infections
Interventions
Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Active, not recruiting No phase listed Observational

Immune Resolution After Staphylococcus Aureus Bacteremia

NCT01879761
View directory record Official record
Conditions
Immune Response To Sepsis, Staphylococcus Aureus Infection
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Completed No phase listed Observational

Chart Review of Outcome of Treatment for S. Aureus Bacteremia

NCT00304902
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 20, 2026, 7:45 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

NCT00695903
View directory record Official record
Conditions
Endocarditis, Bacterial, Infective Endocarditis
Interventions
daptomycin, vancomycin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Greenville, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2018 · Synced Oct 20, 2026, 7:45 PM EDT
Terminated Phase 3 Interventional Results available

Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

NCT04160468
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
Exebacase, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
12 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
55
States / cities
Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 20, 2026, 7:45 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

NCT02208063
View directory record Official record
Conditions
Bacteremia
Interventions
Telavancin, Vancomycin, Daptomycin, Synthetic penicillin, Cefazolin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 4 Interventional

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

NCT02660346
View directory record Official record
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2018 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

NCT04775953
View directory record Official record
Conditions
Staphylococcal Bacteraemia
Interventions
Cefazolin, Dalbavancin, Daptomycin, Nafcillin, Oxacillin, Vancomycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 20, 2026, 7:45 PM EDT
Recruiting Phase 4 Interventional

Staphylococcus Aureus Network Adaptive Platform Trial

NCT05137119
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Cefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics, Whole body FDG PET/CT Imaging
Drug · Other · Radiation
Lead sponsor
University of Melbourne
Other
Eligibility
Not listed
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Enrolling by invitation Phase 4 Interventional

Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?

NCT07148960
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA, Single Agent IV Antibiotic Therapy - MSSA
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 20, 2026, 7:45 PM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia

NCT01701219
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia
Interventions
Ceftaroline fosamil
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 20, 2026, 7:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.

NCT02357966
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
514G3 (2 mg/kg) plus standard IV antibiotic treatment, 514G3 (10 mg/kg) plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment, Placebo plus standard IV antibiotic treatment, 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II, Placebo plus standard IV antibiotic treatment: Phase II
Biological · Other
Lead sponsor
XBiotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Columbus, Georgia • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 20, 2026, 7:45 PM EDT